Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with OtsukaPRNewsWire • 06/30/22
AKBA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBANewsfile Corp • 05/13/22
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022PRNewsWire • 05/13/22
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 05/12/22
AKBA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Akebia Therapeutics, Inc.Newsfile Corp • 05/11/22
AKBA FINAL DEADLINE FRIDAY: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBANewsfile Corp • 05/11/22
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Limited ShareholdersNewsfile Corp • 05/11/22
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action Deadline: May 13, 2022Newsfile Corp • 05/11/22
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)PRNewsWire • 05/11/22
Akebia Class Action: Levi & Korsinsky Reminds Akebia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2022 - AKBANewsfile Corp • 05/10/22
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. ShareholdersPRNewsWire • 05/10/22
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/22
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business UpdatePRNewsWire • 05/09/22
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 DeadlineBusiness Wire • 05/09/22
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBAPRNewsWire • 05/09/22
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022PRNewsWire • 05/09/22
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBANewsfile Corp • 05/04/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBAPRNewsWire • 05/03/22
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/22
ROSEN, Global Investor Counsel, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBANewsfile Corp • 05/02/22
